Cargando…
DLPFC transcriptome defines two molecular subtypes of schizophrenia
Little is known about the molecular pathogenesis of schizophrenia, possibly because of unrecognized heterogeneity in diagnosed patient populations. We analyzed gene expression data collected from the dorsolateral prefrontal cortex (DLPFC) of post-mortem frozen brains of 189 adult diagnosed schizophr...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509343/ https://www.ncbi.nlm.nih.gov/pubmed/31073119 http://dx.doi.org/10.1038/s41398-019-0472-z |
_version_ | 1783417230204076032 |
---|---|
author | Bowen, Elijah F. W. Burgess, Jack L. Granger, Richard Kleinman, Joel E. Rhodes, C. Harker |
author_facet | Bowen, Elijah F. W. Burgess, Jack L. Granger, Richard Kleinman, Joel E. Rhodes, C. Harker |
author_sort | Bowen, Elijah F. W. |
collection | PubMed |
description | Little is known about the molecular pathogenesis of schizophrenia, possibly because of unrecognized heterogeneity in diagnosed patient populations. We analyzed gene expression data collected from the dorsolateral prefrontal cortex (DLPFC) of post-mortem frozen brains of 189 adult diagnosed schizophrenics and 206 matched controls. Transcripts from 633 genes are differentially expressed in the DLPFC of schizophrenics as compared to controls at Bonferroni-corrected significance levels. Seventeen of those genes are differentially expressed at very high significance levels (<10(−8) after Bonferroni correction). The findings were closely replicated in a dataset from an entirely unrelated source. The statistical significance of this differential gene expression is being driven by about half of the schizophrenic DLPFC samples, and importantly, it is the same half of the samples that is driving the significance for almost all of the differentially expressed transcripts. Weighted gene co-expression network analysis (WGCNA) of the schizophrenic subjects, based on the transcripts differentially expressed in the schizophrenics as compared to controls, divides them into two groups. “Type 1” schizophrenics have a DLPFC transcriptome similar to that of controls with only four differentially expressed genes identified. “Type 2” schizophrenics have a DLPFC transcriptome dramatically different from that of controls, with 3529 expression array probes to 3092 genes detecting transcripts that are differentially expressed at very high significance levels. These findings were re-tested and replicated in a separate independent cohort, using the RNAseq data from the DLPFC of an independent set of schizophrenics and control subjects. We suggest the hypothesis that these striking differences in DLPFC transcriptomes, identified and replicated in two populations, imply a fundamental biologic difference between these two groups of diagnosed schizophrenics, and we propose specific paths for further testing and expanding the hypothesis. |
format | Online Article Text |
id | pubmed-6509343 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-65093432019-05-16 DLPFC transcriptome defines two molecular subtypes of schizophrenia Bowen, Elijah F. W. Burgess, Jack L. Granger, Richard Kleinman, Joel E. Rhodes, C. Harker Transl Psychiatry Article Little is known about the molecular pathogenesis of schizophrenia, possibly because of unrecognized heterogeneity in diagnosed patient populations. We analyzed gene expression data collected from the dorsolateral prefrontal cortex (DLPFC) of post-mortem frozen brains of 189 adult diagnosed schizophrenics and 206 matched controls. Transcripts from 633 genes are differentially expressed in the DLPFC of schizophrenics as compared to controls at Bonferroni-corrected significance levels. Seventeen of those genes are differentially expressed at very high significance levels (<10(−8) after Bonferroni correction). The findings were closely replicated in a dataset from an entirely unrelated source. The statistical significance of this differential gene expression is being driven by about half of the schizophrenic DLPFC samples, and importantly, it is the same half of the samples that is driving the significance for almost all of the differentially expressed transcripts. Weighted gene co-expression network analysis (WGCNA) of the schizophrenic subjects, based on the transcripts differentially expressed in the schizophrenics as compared to controls, divides them into two groups. “Type 1” schizophrenics have a DLPFC transcriptome similar to that of controls with only four differentially expressed genes identified. “Type 2” schizophrenics have a DLPFC transcriptome dramatically different from that of controls, with 3529 expression array probes to 3092 genes detecting transcripts that are differentially expressed at very high significance levels. These findings were re-tested and replicated in a separate independent cohort, using the RNAseq data from the DLPFC of an independent set of schizophrenics and control subjects. We suggest the hypothesis that these striking differences in DLPFC transcriptomes, identified and replicated in two populations, imply a fundamental biologic difference between these two groups of diagnosed schizophrenics, and we propose specific paths for further testing and expanding the hypothesis. Nature Publishing Group UK 2019-05-09 /pmc/articles/PMC6509343/ /pubmed/31073119 http://dx.doi.org/10.1038/s41398-019-0472-z Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Bowen, Elijah F. W. Burgess, Jack L. Granger, Richard Kleinman, Joel E. Rhodes, C. Harker DLPFC transcriptome defines two molecular subtypes of schizophrenia |
title | DLPFC transcriptome defines two molecular subtypes of schizophrenia |
title_full | DLPFC transcriptome defines two molecular subtypes of schizophrenia |
title_fullStr | DLPFC transcriptome defines two molecular subtypes of schizophrenia |
title_full_unstemmed | DLPFC transcriptome defines two molecular subtypes of schizophrenia |
title_short | DLPFC transcriptome defines two molecular subtypes of schizophrenia |
title_sort | dlpfc transcriptome defines two molecular subtypes of schizophrenia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509343/ https://www.ncbi.nlm.nih.gov/pubmed/31073119 http://dx.doi.org/10.1038/s41398-019-0472-z |
work_keys_str_mv | AT bowenelijahfw dlpfctranscriptomedefinestwomolecularsubtypesofschizophrenia AT burgessjackl dlpfctranscriptomedefinestwomolecularsubtypesofschizophrenia AT grangerrichard dlpfctranscriptomedefinestwomolecularsubtypesofschizophrenia AT kleinmanjoele dlpfctranscriptomedefinestwomolecularsubtypesofschizophrenia AT rhodescharker dlpfctranscriptomedefinestwomolecularsubtypesofschizophrenia |